ABOUT THIS EPISODE
Dr. Kostas Trakas is a pharma builder and former Johnson & Johnson executive, and co-founder of Exsilios Pharma — a Canadian specialty pharmaceutical company that sources FDA, EMA, and MHRA-approved late-stage assets and secures Canadian commercialization rights across rare disease, oncology, immunology, CNS, and cardiometabolic indications. He holds a PhD and a Master's in pharmacology from the University of Toronto, and spent over a decade at J&J in global marketing and market access leadership, including building companion diagnostic policy platforms and public-private partnership models across EMEA and LatAm. Before Exsilios, he led Exactis Innovation, taking Canada's largest oncology real-world evidence network from a grant-funded model toward commercial self-sufficiency. He writes and speaks publicly on where Canada's Life Sciences Task Force has fallen short, and is currently pivoting Exsilios toward developing early-stage Canadian IP into a genuine anchor company.
In this conversation, Dr. Trakas and Natalie trace the entire pipeline from the ground up. It starts with the argument that Canada's most underused strategic asset isn't a new discovery at all — it's the tokenized, longitudinally-linked health data sitting inside a single-payer system, an asset the fragmented, privately-insured US system structurally can't replicate, and one Canada still won't let researchers actually access. From there it moves into funding: Dr. Trakas's own experience inheriting ten years of grant-funded operations and being told to make them commercially self-sufficient, his blunt dismissal of Canada's incubator and accelerator model as "checkbox" theatre, and the pension fund paradox where the Maple Eight are structurally barred by their own fiduciary rules from investing in the small domestic companies that need them most — a policy Canada wrote into its own regulations roughly twenty years ago and has never revisited.
The conversation turns next to why Canadian founders default to selling rather than building — Dr. Trakas's own theory that Canadians settle for being what he calls the "second banana," happy to sell at the first good offer rather than aspiring to build the next Shopify — and what it would actually take to produce Canada's first true anchor companies and the biotech clusters that follow them. From there they dismantle the reimbursement gauntlet directly: Dr. Trakas's case for collapsing the PMPRB, CDA-AMC, and pCPA into a single agency instead of three sequential closed-door negotiations that can take a product two years to reach a single provincial formulary, set against the reality that Canadians access only about 18% of globally available medicines versus an OECD average of 28%. The episode closes on the geopolitical stakes: China's decade-long playbook of steel, then EVs, now life sciences, and why Dr. Trakas believes Canada can run the same playbook rather than keep funding runway for other countries to take off.
This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.
If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.
🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.
🔗 Questions, feedback, or want to connect? https://augmentios.com/contact
📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter
#BreakingInnovationParalysis #CanadianInnovation #InnovationEcosystem #LifeSciences #Biotech #Pharma #InnovationPolicy #EconomicSovereignty
